BTAI

Bioxcel Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 0/10
Bioxcel Therapeutics sales and earnings growth
BTAI Growth
Good
  • Revenue Y/Y↓ -66.96%
  • EPS Y/Y↑ 73.93%
  • FCF Y/Y↑ 30.76%
Bioxcel Therapeutics gross and profit margin trends
BTAI Profitability
Low
  • Gross margin ↓ -28.20%
  • EPS margin↓ -9070.60%
  • ROIC 5Y↓ -151.28%
Bioxcel Therapeutics net debt vs free cash flow
BTAI Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 1.2
  • Interest coverage↓ -3.1

Bioxcel Therapeutics stock volatility is higher than the overall market. We give it a Poor risk rating.

More Biotechnology stocks ↗